We have outlined the importance of 1) including a broader approach to platelet function studies during clinical trials; 2) the contribution of collagen-mediated platelet activation in diseases/conditions such as CAD, MI and stroke; and 3) the potential role of colchicine in targeting collagen receptor pathways. This evidence concerns the gene ITGA2 and stroke disorder.